ATE507241T1 - Rekombinante polypeptide auf triplex-gerüst-basis - Google Patents

Rekombinante polypeptide auf triplex-gerüst-basis

Info

Publication number
ATE507241T1
ATE507241T1 AT06291927T AT06291927T ATE507241T1 AT E507241 T1 ATE507241 T1 AT E507241T1 AT 06291927 T AT06291927 T AT 06291927T AT 06291927 T AT06291927 T AT 06291927T AT E507241 T1 ATE507241 T1 AT E507241T1
Authority
AT
Austria
Prior art keywords
scaffold
triplex
recombinant polypeptides
based recombinant
disclosed
Prior art date
Application number
AT06291927T
Other languages
English (en)
Inventor
Min-Yuan Chou
Chia-Yu Fan
Chuan-Chuan Huang
Hsiu-Chuan Li
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Application granted granted Critical
Publication of ATE507241T1 publication Critical patent/ATE507241T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
AT06291927T 2005-12-15 2006-12-14 Rekombinante polypeptide auf triplex-gerüst-basis ATE507241T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75074605P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
ATE507241T1 true ATE507241T1 (de) 2011-05-15

Family

ID=37963680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06291927T ATE507241T1 (de) 2005-12-15 2006-12-14 Rekombinante polypeptide auf triplex-gerüst-basis

Country Status (10)

Country Link
US (1) US20070264687A1 (de)
EP (3) EP2336170A3 (de)
JP (2) JP2007181458A (de)
AT (1) ATE507241T1 (de)
AU (1) AU2006252078B2 (de)
CA (1) CA2569062A1 (de)
DE (1) DE602006021520D1 (de)
DK (1) DK1798240T3 (de)
ES (1) ES2365744T3 (de)
TW (1) TWI373475B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183986B2 (en) * 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
ES2593049T3 (es) * 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
ES2371426B1 (es) * 2009-04-20 2013-05-10 Universidad Autónoma de Madrid Proteinas oligomericas y sus aplicaciones
WO2010122181A1 (es) * 2009-04-20 2010-10-28 Universidad Autónoma de Madrid Proteínas oligoméricas y sus aplicaciones
CA2800595C (en) * 2010-05-26 2018-04-24 Shriners Hospitals For Children Compositions comprising the nc2 domain of collagen ix and methods of using same
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
BR112014029403A2 (pt) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugados, anticorpo e formulação farmacêutica
EP3019533B1 (de) * 2013-07-11 2020-01-08 The Scripps Research Institute Doppelwendel-immunglobulinfusionsproteine und zusammensetzungen daraus
CN103454265A (zh) * 2013-08-09 2013-12-18 北京润诺思医疗科技有限公司 一种糖尿病预测标志物-纤维胶凝蛋白-3(Ficolin-3)化学发光定量检测试剂盒及其制备方法
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
ES2895752T3 (es) 2014-01-03 2022-02-22 Hoffmann La Roche Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
CN106687476B (zh) 2014-06-26 2020-11-13 豪夫迈·罗氏有限公司 抗brdu抗体及使用方法
EP3436484B1 (de) 2016-03-30 2025-10-01 AB Biosciences, Inc. Zusammensetzungen aus rekombinantem intravenösem immunglobulin (rivig) und verfahren zu deren herstellung und verwendung
US12516292B2 (en) 2016-07-25 2026-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing modified natural killer cells and methods of use
CN109844099B (zh) * 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) 产生经修饰的自然杀伤细胞的方法及使用方法
JPWO2019124461A1 (ja) * 2017-12-19 2020-12-24 国立大学法人北海道大学 抗体断片多量体分子、医薬品、抗腫瘍剤、自己免疫疾患治療剤及び抗体断片多量体分子の作製方法
CN109293774B (zh) * 2018-10-16 2021-05-28 南京医科大学 特异性结合cd19的全人源化抗体及应用
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022109611A1 (en) 2020-11-20 2022-05-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
CN114409802B (zh) * 2020-12-31 2023-10-20 中国科学院微生物研究所 禽流感病毒三聚体亚单位疫苗及其应用
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4433506A1 (de) 2021-11-16 2024-09-25 Genentech, Inc. Verfahren und zusammensetzungen zur behandlung von systemischem lupus erythematodes (sle) mit momonetuzumab
WO2023227018A1 (zh) * 2022-05-25 2023-11-30 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用
CN114957491B (zh) * 2022-06-29 2023-05-23 湖北工业大学 一种靶向结合β-catenin蛋白的多肽、多肽衍生物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0768377A1 (de) 1988-09-02 1997-04-16 Protein Engineering Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
GB9409768D0 (en) * 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US6187907B1 (en) * 1998-08-31 2001-02-13 James Chen Triple helix coil template having a biologically active ligand
JP2000125872A (ja) * 1998-09-07 2000-05-09 Terumo Corp 三量体キメラタンパク質およびキメラタンパク質を含有するコラーゲンマトリックス
ES2276735T3 (es) * 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
WO2005037852A2 (en) * 2003-08-22 2005-04-28 Barnes-Jewish Hospital Trimerizing polypeptides and their uses
WO2005070966A2 (en) * 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
EP1798240B1 (de) 2011-04-27
EP2336170A2 (de) 2011-06-22
TW200734354A (en) 2007-09-16
TWI373475B (en) 2012-10-01
JP2011217760A (ja) 2011-11-04
ES2365744T3 (es) 2011-10-10
AU2006252078B2 (en) 2008-09-25
EP1798240A1 (de) 2007-06-20
JP5544534B2 (ja) 2014-07-09
US20070264687A1 (en) 2007-11-15
CA2569062A1 (en) 2007-06-15
EP2338912A3 (de) 2012-04-18
DK1798240T3 (da) 2011-05-23
EP2336170A3 (de) 2012-04-25
EP2338912A2 (de) 2011-06-29
AU2006252078A1 (en) 2007-07-05
JP2007181458A (ja) 2007-07-19
DE602006021520D1 (de) 2011-06-09

Similar Documents

Publication Publication Date Title
DK1798240T3 (da) Rekombinante triplex scaffold-baserede polypeptider
MX2021000047A (es) Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma.
MX2021000263A (es) Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
EP2468768A3 (de) Mehrfache Genexpression mit sORF-Konstrukten und Verfahren mit Polyproteinen, Pro-Proteinen und Proteolyse
ATE454393T1 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
WO2008008975A3 (en) Refolding of recombinant proteins
TW200732472A (en) Method for the recombinant expression of a polypeptide
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
WO2002099070A3 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
WO2013091661A3 (en) Proteolytic resistant protein affinity tag
WO2004097001A3 (en) Novel bacillus 029cel cellulase
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
DE60227285D1 (de) Rekombinante polypeptide
DK1639104T3 (da) Forbedrede proteaser og fremgangsmåder til fremstilling af disse
TW200510456A (en) Materials and methods relating to g-protein coupled receptor oligomers
DE60330489D1 (de) Schnell abgebaute reporter-fusionsproteine
TW200722436A (en) A peptide-immunoglobulin-conjugate
WO2006076742A3 (en) Methods and compositions for increasing membrane permeability
WO2025015294A3 (en) Modified leaf-branch compost cutinase polypeptides with improved polyethylene terephthalate degrading activity
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
WO2019046446A3 (en) COMPOSITIONS AND METHODS USING METHANOTROPHE LAYER PROTEINS FOR THE EXPRESSION OF HETEROLOGOUS PROTEINS
NO20085201L (no) Rekombinante novirhabdoviruser og deres anvendelse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1798240

Country of ref document: EP